DIO-901- Nocturnal Hypoglycemia
DIO-901 (a very low dose glucagon) is in development for the prevention of nocturnal hypoglycemia in diabetes. The Phase 1 program demonstrated dose dependent increases in plasma glucagon and blood glucose, hypoglycemia was delayed or averted and very low dose glucagon was safe and well tolerated. The FDA has granted Fast Track designation to the program.
Read more about this topic: Camurus, Pharmaceuticals
Famous quotes containing the word nocturnal:
“All architecture is great architecture after sunset; perhaps architecture is really a nocturnal art, like the art of fireworks.”
—Gilbert Keith Chesterton (1874–1936)